Selinexor (KPT-330) is a first-in-class novel, oral potent inhibitor of XPO1 and was shown to inhibit tumor growth by blocking the nuclear-cytoplasmic transport mechanism and interfering DNA damage repair (DDR) mechanism in preclinical models [16–18]. This evidence concerns the gene XPO1 and neoplasm.